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Background and PurposeᄏRestless legs syndrome (RLS) is a sleep disorder that frequently 
occurs in dialysis patients, which disturbs the sleep and reduces the quality of life. The aim of 
this study was to determine the risk factors for RLS in dialysis patients. 
MethodsᄏPatients who visited any of four outpatient dialysis clinics between September 2005 
and May 2006 were included in this study. The diagnosis of RLS and the severity assessment 
were made using the criteria described by the International Restless Legs Syndrome Study 
Group. We collected basic demographic data, clinical information, and laboratory findings, and 
then analyzed their association with various aspects of RLS using univariate and multivariate 
analyses. 
ResultsᄏRLS was present in 46 (28.0%) of 164 dialysis patients. We found no significant risk 
factor for inducing RLS. The predialysis serum blood urea nitrogen (BUN) level in the dialy-
sis patients with RLS was significantly correlated with RLS symptom severity. 
ConclusionsᄏPredialysis BUN is related to RLS symptom severity. Further studies on the 
underlying mechanism are needed.  J Clin Neurol 2008;4:153-157
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Introduction 
 
Restless legs syndrome (RLS) is one of the most commonly 
encountered sleep disorders, and it is diagnosed when the 
following four essential criteria are met: 1) the urge to move 
the legs, usually with unpleasant sensations; 2) the appear-
ance of symptoms during inactivity or rest; 3 ) relief with 
movement; and 4) worsening of symptoms in the evening or 
at night.
1 There have been significant recent advances in 
knowledge of the etiology, pathophysiology, risk factors, and 
treatment of RLS. The most frequently reported causes of 
secondary RLS are iron deficiency, neurological lesion on a 
peripheral nerve or the spinal cord, uremia, and medications, 
which are frequent medical problems among patients with 
chronic renal disease.
2 
Sleep disorders are common among patients undergoing 
dialysis for end-stage renal disease.
3 Patients undergoing re-
gular dialysis frequently complain of insomnia, RLS, sleep-
disordered breathing, and excessive daytime sleepiness.
3 The 
prevalence of RLS is higher in dialysis populations than in 
the general population, but there is a wide variation even af-
ter applying unified diagnostic criteria.
2,4,5 It is suggested that 
racial differences in RLS susceptibility, environmental fac-
tors such as geographic location, and methodological limitat-
ions including small study samples and inconsistent inter-
pretation of diagnostic criteria could result in this wide vari-
ation of the prevalence.
6,7 Many authors have proposed risk 
factors for RLS, but many results of previous studies have 
been inconsistent. Being female, a longer duration of dialysis, 
iron deficiency, and the use of medications such as tricyclic 
antidepressant or dopaminergic antagonist have been consi-
dered risk factors for RLS among dialysis patients.
2 It is im-
portant to be aware of the prevalence and risk factors of RLS 
because the presence of RLS might indicate incorrect dialy-
sis treatment and reduce the quality of life in dialysis pa-
tients.
8-10 The present study aimed to elucidate the preval- 
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ence of RLS in patients undergoing hemodialysis in Korea 
and to disclose the underlying causative factors.   
  
Methods 
 
Patients who visited any of four outpatient dialysis clinics in 
Seoul, Korea between September 2005 and May 2006 were 
included in this study. The patients had to have received re-
gular hemodialysis for at least 3 months. Patients who re-
fused to participate in the study or who were unable to com-
municate were excluded. A total of 164 out of 321 patients 
who were receiving regular dialysis treatment were included 
in this study. Demographic and clinical information was ob-
tained by reviewing patient records. The basic data collected 
related to the age, gender, duration of dialysis therapy, renal-
disease history, comorbid-disease history, body mass index 
(BMI), and weight. The following laboratory data were also 
obtained: predialysis blood urea nitrogen (BUN), creatinine, 
hemoglobin, serum iron, ferritin, total iron-binding capacity 
(TIBC), phosphate, total calcium, parathyroid hormone 
(PTH), total bilirubin, alanine aminotransferase (ALT), vita-
min B12, and folate. Information was also obtained on the pa-
tients’ current medications. One of the investigators (J.M.K.) 
performed face-to-face interviews based on the questionnaire 
during the dialysis sessions and, if necessary, examined pa-
tients to exclude other diseases mimicking RLS. The question-
naire comprised two pages. The first page included the Korean 
version of the Epworth sleep scale (ESS) and four diagnostic 
criteria proposed by the International RLS Study Group 
(IRLS-SG).
1 An ESS score greater than nine was considered 
abnormal. Only patients who fulfilled the four criteria for RLS 
were asked to complete the second page of the questionnaire. 
The second page contained the 10-question IRLSSG Rat-
ing Scale, which was used to assess symptom severity.
11  
Continuous data are presented here as mean±standard de-
viation (SD) values. Univariate analysis was used to compare 
data between patients with and without RLS. A multivariate 
logistic model was created with RLS as the dependent vari-
able. We applied Pearson’s correlation analysis between mul-
tiple variables and scores on the IRLSSG Rating Scale in the 
patients with RLS. p<0.05 was considered statistically signi-
ficant. Statistical analysis was carried out using SPSS 12.0 K 
software. 
  
Results 
 
Forty-six (28.0%) of the 164 dialysis patients fulfilled the 
diagnostic criteria of RLS. The age of the study patients was 
62.2±12.7 years. The etiology of renal disease included dia-
betic nephropathy in 84 patients, hypertensive nephropathy 
in 27 patients, glomerulonephritis in 21 patients, and mis-
cellaneous conditions (e.g., autosomal dominant polycystic 
kidney disease, drug-induced nephritis, and paraproteinemia) 
in 18 patients. The etiology was inconclusive in 14 patients. 
Erythropoietin was prescribed in 151 (92.1%) patients, oral 
or parenteral iron supplements were prescribed in 152 pa-
tients (92.7%), and vitamin B12 was prescribed in 156 pa-
tients  (95.1%). None of the patients were treated with a 
dopa agonist. The basic demographic data of the patients are 
presented in Table 1. 
Comparing the clinical characteristics of patients with and 
without RLS by univariate analysis revealed that none of the 
variables was associated with the presence of RLS (Table 2). 
Daytime sleepiness as measured by the ESS did not differ 
between patients in the RLS and non-RLS groups (p=0.841). 
We conducted multivariate logistic regression analysis using 
variables for which the probability was less than 0.20; that is, 
age, hemoglobin, iron, and ALT (Table 3). None of the vari-
ables differed significantly between the RLS and non-RLS 
groups, but RLS patients tended to be younger (p=0.053). 
Predialysis BUN level and symptom severity as measured by 
the IRLSSG Rating Scale were correlated in the RLS group 
(p=0.05, r=0.363), as indicated in Table 4 and Fig. 1. 
Table 1. Baseline characteristics of patients enrolled from four 
dialysis clinics 
Total number of patients  164 
Age (years)  62.2±12.7 
Score on ESS  5.20±4.83 
Duration of dialysis (years)  5.11±4.83 
Height (cm)  162±8.5 
Weight (kg)  60.3±10.7 
BMI (kg/m2)  22.5±3.8 
Number of female patients  072 
Renal-disease etiology (number of patients)  
Diabetes  84 (51.2%)
Hypertension  27 (16.5%)
Glomerulonephritis  21 (12.8%)
Others  18 (11.0%)
Unknown  14 (8.5%)0
Comorbid diseases (number of patients)  
Diabetes  124 
Hypertension  109 
Hepatitis  012 
Number of patients with RLS  046 
RLS severity on IRLSSG Rating Scale  
Mild (1-10)  18 (39.1%)
Moderate (11-20)  21 (45.7%)
Severe (21-30)  07 (15.2%)
ESS: Epworth sleep scale, BMI: body mass index, RLS: restless legs
syndrome, IRLSSG:  International Restless Legs Syndrome Study 
Group. 
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Discussion 
 
This study revealed that the frequency of RLS among dia-
lysis patients in Korea is 28.0%, which is markedly higher 
than the prevalence of RLS in the general Korean population 
(12.1%).
12 The diagnosis of RLS in this study was based on 
Table 2. Summary of univariate analysis results 
 
Patients with 
RLS 
Patients without 
RLS 
p 
Female patients  23  49  0.326
Diabetes 33  91  0.471
Hepatitis  02 10  0.362
ESS  0005.70±3.84  0005.20±3.63 0.272
Daytime sleepiness*  08 19  0.841
Age (years)  00059.2±13.1  00063.4±12.4 0.057
Duration of dialysis 
 (years) 
0005.13±5.43 
 
0005.10±4.60 
 
0.974
Body weight (kg)  00059.7±11.7  00060.5±10.3 0.657
BMI (kg/m2)  00022.7±3.6  00022.4±3.9 0.679
BUN (mg/dL)  0058.70±22.78  0058.65±24.69  0.990
Urea reduction ratio (%)  00072.9±5.1  00071.9±7.4 0.715
Creatinine (mg/dL)  0008.94±2.63  0009.56±4.37 0.373
Phosphate (mmoL/L)  0004.57±1.77  0004.61±1.59 0.876
Hb (g/L)  0010.98±1.46  0010.63±1.46 0.172
Iron (μg/dL)  0070.44±24.92  0062.41±31.23  0.127
Ferritin (mg/L)  0291.89±264.53 0293.49±322.77  0.977
TIBC (μg/dL)  0226.29±41.03  0217.51±47.54  0.281
PTH (pg/mL)  0177.34±162.6  00149.2±168.0  0.399
Vitamin B12 (pg/mL) 1792.91±1042.6 02045.9±1225.1  0.398
Folate (ng/mL)  00112.8±94.4  00129.7±100.3  0.405
Total bilirubin (mg/dL)  0000.50±0.24  0000.46±0.18 0.217
ALT (IU/L)  00023.7±30.7  00016.4±13.4 0.125
*Patients with an ESS score greater than 9 were considered to
have daytime sleepiness. 
RLS: restless legs syndrome, ESS: Epworth sleep scale, BMI: body 
mass index, BUN: blood urea nitrogen, Hb: hemoglobin, TIBC:
total iron-binding capacity, PTH: parathyroid hormone, ALT: al-
anine aminotransferase. 
 
Table 4. Results of pearson’s correlation analysis 
    ESS  IRLSSG rating scale  Age  Dialysis duration  BMI  Hb  Iron  Ferritin  BUN 
ESS  r 
p 
 
-0.025 
-0.867 
-0.054 
-0.722 
-0.059 
-0.698 
-0.122 
-0.420 
-0.058 
-0.700 
-0.146 
-0.338 
-0.096 
-0.530 
-0.122 
-0.418 
IRLSSG rating scale  r 
p 
0.025 
0.867 
 
-0.081 
-0.592 
-0.172 
-0.253 
-0.131 
-0.385 
-0.142 
-0.346 
-0.016 
-0.915 
-0.043 
-0.780 
-0.363* 
-0.013 
Age  r 
p 
-0.054 
0.722 
-0.081 
-0.592 
 
-0.272 
-0.067 
-0.356* 
-0.015 
-0.259 
-0.082 
-0.130 
-0.395 
-0.100 
-0.513 
-0.224 
-0.134 
Dialysis duration  r 
p 
-0.059 
0.698 
-0.172 
-0.253 
-0.272 
-0.067 
 
-0.287 
-0.053 
-0.156 
-0.302 
-0.200 
-0.187 
-0.050 
-0.744 
-0.083 
-0.582 
BMI  r 
p 
0.122 
0.420 
-0.131 
-0.385 
-0.356* 
-0.015 
-0.287 
-0.053 
 
-0.161 
-0.079 
-0.061 
-0.689 
-0052 
-0.736 
-0.123 
-0.417 
Hb  r 
p 
0.058 
0.700 
-0.142 
-0.346 
-0.259 
-0.082 
-0.156 
-0.302 
-0.262 
-0.079 
 
-0.121 
-0.430 
-0.049 
-0.750 
-0.019 
-0.899 
Iron  r 
p 
0.146 
0.338 
-0.166 
-0.915 
-0.130 
-0.395 
-0.200 
-0.187 
-0.061 
-0.689 
-0.121 
-0.430 
 
-0.021 
-0.893 
-0.006 
-0.969 
Ferritin  r 
p 
-0.096 
0.530 
-0.043 
-0.780 
-0.100 
-0.513 
-0.050 
-0.744 
-0.052 
-0.736 
-0.049 
-0.750 
-0.021 
-0.893 
 
-0.023 
-0.880 
BUN  r 
p 
-0.122 
0.418 
-0.363* 
-0.013 
-0.224 
-0.134 
-0.083 
-0.582 
-0.123 
-0.417 
-0.019 
-0.899 
-0.006 
-0.969 
-0.023 
-0.880 
 
*p<0.05. 
ESS: Epworth sleep scale, IRLSSG: International Restless Legs Syndrome Study Group, BMI: body mass index, Hb: hemoglobin, BUN: blood 
urea nitrogen. 
 
Table 3. Results of multivariate analysis of risk factors for RLS
  Odds ratio  95% Confidence ratio  p 
Age 0.972  0.944-1.000 0.053 
Hb 1.132  0.879-1.460 0.337 
Iron 1.008  0.997-1.021 0.165 
ALT 1.015  0.995-1.036 0.138 
RLS: restless legs syndrome, Hb: hemoglobin, ALT: alanine ami-
notransferase. 
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Fig. 1. The predialysis blood urea nitrogen (BUN) level was signi-
ficantly correlated with scores on the IRLSSG (International Re-
stless Legs Syndrome Study Group) Rating Scale.  
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the four strict criteria proposed by the IRLSSG, and the pa-
tients were examined by an experienced neurologist in face-to-
face interviews, which made the diagnoses highly reliable. 
The prevalence of RLS in our Korean population was higher 
than that reported for populations in Japan (12.2%) and India 
(6.6%), lower than that reported for China (62%),
4,5,13 and si-
milar to that reported for Chile (25.9%) and Italy (21.5%).
14,15 
This wide variation suggests different susceptibilities to RLS 
or methodological differences in study populations.
2,6,7  
Many studies have recently been conducted in dialysis 
clinics to clarify the risk factors for RLS, but the results have 
varied widely. We found no significant association between 
RLS and any of the following factors: age, gender, duration 
of dialysis, comorbid diseases, BMI, and laboratory data in-
cluding hemoglobin, BUN, creatinine, iron, ferritin, TIBC, 
PTH, folate, phosphate, ALT, and total bilirubin. One of the 
interesting results of this study is that the predialysis BUN 
level was significantly correlated with symptom severity in 
the RLS group, although the predialysis BUN level did not 
differ between the RLS and non-RLS groups. The predialy-
sis BUN level is not a recommended indicator of dialysis ef-
ficiency or disease severity because it is easily influenced by 
protein intake, body volume, and energy metabolism.
16 Our 
results suggest that factors other than dialysis adequacy-such 
as dietary protein intake, recent infection, or body volume-are 
related to worsening of RLS. These factors might not play a 
major role in RLS development, but they could aggravate 
RLS symptoms once the syndrome appears. Detailed clinical 
data including body weight change, medication profile, and 
diet might help to disclose the underlying mechanism. Iron-
deficiency anemia is a well-known risk factor for RLS, and 
the level of serum ferritin is known to be correlated with RLS 
severity in some RLS patients, suggesting a close relationship 
between iron metabolism and the pathophysiology of RLS.
2 
However, this relationship is less clear in RLS among dialy-
sis patients, presumably due to the routine use of iron supple-
mentation in this population.
2,17 In our study, 92.7% of all 
patients were regularly supplemented with iron, and this could 
have alleviated the effects of hemoglobin, iron, and ferritin. 
The level of ferritin was also not correlated with symptom se-
verity. Routine supplementation with iron could also explain 
the large proportion of patients with mild RLS (39.1%) in 
the RLS group. Aging is also believed to be a risk factor for 
idiopathic RLS.
18 However, previous studies have shown that 
this is not always true in RLS patients undergoing dialysis.
19 
The RLS patients in our study tended to be younger, which 
suggests that RLS-inducing factors are stronger than the ag-
ing effect in dialysis patients. Some studies have found a fe-
male preponderance in RLS, while others have found no 
gender difference or even a possible male predominance in 
RLS.
20,21 We found no female predominance in our RLS pa-
tients. The duration of dialysis therapy is generally regarded as 
a risk factor for RLS,
22 but this was not evident in our study. 
We also could found no association between a high BMI and 
RLS in our dialysis patients.
17,21  
Daytime sleepiness as measured by the ESS did not differ 
between the two groups in the present study, which is incon-
sistent with previous reports.
3,23 Since our study population 
included many diabetic patients, the accompanying retinopa-
thy prevented us from obtaining accurate ESS scores because 
such patients are unable to drive a car, watch TV, or read 
newspapers. Therefore, this might not be an appropriate mo-
dality for assessing sleep disturbance in diabetic patients. 
A previous study suggested that the prevalence of RLS 
among dialysis patients in Korea was 44.0%.
24 The lower 
prevalence found in our study might be due to our method of 
face-to-face questioning combined with a neurological ex-
amination yielding more accurate diagnoses than those based 
on questionnaires and different biological properties, in-
cludeing age and duration of dialysis. Questionnaire-based 
diagnoses of RLS might be unreliable in uremic patients due 
to low sensitivity and specificity.
25 False-positive results 
appear to be caused by the presence of other leg-related symp-
toms and neurologically objective signs suggestive of peri-
pheral neuropathy.
25  
Our study had some limitations. The first is the inevitable 
selection bias from collecting data from only 164 out of a total 
of 321 patients. The main cause of exclusion was communi-
cation difficulties, which might have excluded all of the most 
severe patients. The second limitation was insufficient data 
on medication history. Our patients were taking many drugs, 
including benzodiazepines, gabapentin, tricyclic antidepres-
sants, and calcium-channel antagonists, and we could not rule 
out their role in RLS. Finally, we did not obtain data on nerve 
conduction parameters because most of the patients did not 
agree to undergo such investigations. However, we attempted 
to exclude other diseases that could mimic RLS by perform-
ing a structured interview and neurological examination.   
RLS is common in patients undergoing regular hemodialy-
sis. More attention to this disease might aid its detection and 
reduce patient discomfort. Further studies are needed to dis-
close its detailed risk factors and the pathophysiological role 
of the BUN level in RLS. 
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